Halloran Consulting Group

Executive Summary

Halloran Consulting Group, a Boston-based life science consulting firm founded in 1998, provides integrated regulatory, quality, and clinical development services to pharmaceutical, biotechnology, and medical device companies. With over 25 years of experience, the firm partners with clients to advance products from early development through commercialization, leveraging deep expertise in FDA and global regulatory pathways. As a private company, Halloran has built a reputation for delivering strategic guidance that accelerates timelines and mitigates risks, serving a diverse client base ranging from startups to established enterprises. The current regulatory landscape, characterized by evolving FDA guidances and increasing demand for expedited clinical development, positions Halloran to capitalize on growing outsourcing trends. The firm's comprehensive service suite and seasoned team enable it to address complex challenges in areas such as orphan drug designations, breakthrough therapy designations, and digital health integrations. While private financial details are undisclosed, Halloran's sustained market presence suggests stable demand. Future growth will likely depend on expanding its client portfolio and adapting to emerging modalities like cell and gene therapies.

Upcoming Catalysts (preview)

• Q3 2026Major partnership with a top-10 pharmaceutical company for regulatory support50% success
• Q4 2026Launch of a dedicated digital health consulting practice60% success
• Q2 2026Publication of a thought leadership report on FDA's accelerated approval pathways80% success